EICHOR
● Recruiting
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Condition: Metastatic Pancreatic Ductal Adenocarcinoma · Pancreatic Cancer · Cancer of the Pancreas · Sponsor: Washington University School of Medicine
About this study
The investigators hypothesize that MK2 inhibition may improve efficacy of mFOLFIRINOX chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC).
This description comes directly from the study's public registry record.
Talk to the study team
Moh'd Khushman, M.D. · 314-273-3564 · mkhushman@wustl.edu
Always discuss trial participation with your own doctor first.
Locations (1)
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06648434